vs

Side-by-side financial comparison of PRECISION BIOSCIENCES INC (DTIL) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

PRECISION BIOSCIENCES INC is the larger business by last-quarter revenue ($34.2M vs $22.2M, roughly 1.5× USCB FINANCIAL HOLDINGS, INC.). PRECISION BIOSCIENCES INC runs the higher net margin — 58.9% vs 6.1%, a 52.7% gap on every dollar of revenue. On growth, PRECISION BIOSCIENCES INC posted the faster year-over-year revenue change (5261.1% vs 14.7%). USCB FINANCIAL HOLDINGS, INC. produced more free cash flow last quarter ($42.5M vs $-11.3M). Over the past eight quarters, PRECISION BIOSCIENCES INC's revenue compounded faster (39.5% CAGR vs 12.3%).

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

DTIL vs USCB — Head-to-Head

Bigger by revenue
DTIL
DTIL
1.5× larger
DTIL
$34.2M
$22.2M
USCB
Growing faster (revenue YoY)
DTIL
DTIL
+5246.4% gap
DTIL
5261.1%
14.7%
USCB
Higher net margin
DTIL
DTIL
52.7% more per $
DTIL
58.9%
6.1%
USCB
More free cash flow
USCB
USCB
$53.8M more FCF
USCB
$42.5M
$-11.3M
DTIL
Faster 2-yr revenue CAGR
DTIL
DTIL
Annualised
DTIL
39.5%
12.3%
USCB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DTIL
DTIL
USCB
USCB
Revenue
$34.2M
$22.2M
Net Profit
$20.1M
$1.4M
Gross Margin
Operating Margin
36.6%
14.7%
Net Margin
58.9%
6.1%
Revenue YoY
5261.1%
14.7%
Net Profit YoY
213.5%
-80.3%
EPS (diluted)
$2.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DTIL
DTIL
USCB
USCB
Q4 25
$34.2M
$22.2M
Q3 25
$13.0K
$25.0M
Q2 25
$18.0K
$24.4M
Q1 25
$29.0K
$22.8M
Q4 24
$638.0K
$23.0M
Q3 24
$576.0K
$21.5M
Q2 24
$49.9M
$20.5M
Q1 24
$17.6M
$17.6M
Net Profit
DTIL
DTIL
USCB
USCB
Q4 25
$20.1M
$1.4M
Q3 25
$-21.8M
$8.9M
Q2 25
$-23.5M
$8.1M
Q1 25
$-20.6M
$7.7M
Q4 24
$6.9M
Q3 24
$-16.4M
$6.9M
Q2 24
$32.7M
$6.2M
Q1 24
$8.6M
$4.6M
Operating Margin
DTIL
DTIL
USCB
USCB
Q4 25
36.6%
14.7%
Q3 25
-158976.9%
47.3%
Q2 25
-121538.9%
44.0%
Q1 25
-76248.3%
44.2%
Q4 24
39.6%
Q3 24
-3693.6%
42.5%
Q2 24
48.4%
39.8%
Q1 24
-23.8%
34.3%
Net Margin
DTIL
DTIL
USCB
USCB
Q4 25
58.9%
6.1%
Q3 25
-167476.9%
35.8%
Q2 25
-130666.7%
33.4%
Q1 25
-70913.8%
33.5%
Q4 24
30.0%
Q3 24
-2851.6%
32.3%
Q2 24
65.6%
30.3%
Q1 24
48.8%
26.2%
EPS (diluted)
DTIL
DTIL
USCB
USCB
Q4 25
$2.62
Q3 25
$-1.84
$0.45
Q2 25
$-2.13
Q1 25
$-2.21
Q4 24
Q3 24
$-2.25
$0.35
Q2 24
$4.67
Q1 24
$1.70

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DTIL
DTIL
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$115.6M
$38.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$92.2M
$217.2M
Total Assets
$154.4M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DTIL
DTIL
USCB
USCB
Q4 25
$115.6M
$38.5M
Q3 25
$44.9M
$56.8M
Q2 25
$62.2M
$54.8M
Q1 25
$77.2M
$98.0M
Q4 24
$86.3M
$77.0M
Q3 24
$101.2M
$38.5M
Q2 24
$123.6M
$77.3M
Q1 24
$137.8M
$126.5M
Stockholders' Equity
DTIL
DTIL
USCB
USCB
Q4 25
$92.2M
$217.2M
Q3 25
$16.6M
$209.1M
Q2 25
$34.1M
$231.6M
Q1 25
$49.3M
$225.1M
Q4 24
$56.4M
$215.4M
Q3 24
$64.9M
$213.9M
Q2 24
$74.7M
$201.0M
Q1 24
$37.2M
$195.0M
Total Assets
DTIL
DTIL
USCB
USCB
Q4 25
$154.4M
$2.8B
Q3 25
$93.5M
$2.8B
Q2 25
$108.9M
$2.7B
Q1 25
$124.4M
$2.7B
Q4 24
$136.4M
$2.6B
Q3 24
$153.3M
$2.5B
Q2 24
$165.8M
$2.5B
Q1 24
$184.7M
$2.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DTIL
DTIL
USCB
USCB
Operating Cash FlowLast quarter
$-11.3M
$42.8M
Free Cash FlowOCF − Capex
$-11.3M
$42.5M
FCF MarginFCF / Revenue
-32.9%
191.4%
Capex IntensityCapex / Revenue
0.1%
1.4%
Cash ConversionOCF / Net Profit
-0.56×
31.40×
TTM Free Cash FlowTrailing 4 quarters
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DTIL
DTIL
USCB
USCB
Q4 25
$-11.3M
$42.8M
Q3 25
$-15.3M
$20.1M
Q2 25
$-20.3M
$18.0M
Q1 25
$-19.1M
$14.6M
Q4 24
$-58.4M
$34.8M
Q3 24
$-5.9M
$11.3M
Q2 24
$-14.9M
$18.3M
Q1 24
$-19.0M
$8.1M
Free Cash Flow
DTIL
DTIL
USCB
USCB
Q4 25
$-11.3M
$42.5M
Q3 25
$20.0M
Q2 25
$-20.3M
$18.0M
Q1 25
$-19.1M
$14.6M
Q4 24
$-58.7M
$34.5M
Q3 24
$-6.0M
$11.2M
Q2 24
$-14.9M
$18.2M
Q1 24
$-19.1M
$8.0M
FCF Margin
DTIL
DTIL
USCB
USCB
Q4 25
-32.9%
191.4%
Q3 25
80.3%
Q2 25
-112627.8%
73.7%
Q1 25
-65917.2%
63.9%
Q4 24
-9199.8%
150.2%
Q3 24
-1033.2%
52.2%
Q2 24
-29.9%
88.8%
Q1 24
-108.4%
45.4%
Capex Intensity
DTIL
DTIL
USCB
USCB
Q4 25
0.1%
1.4%
Q3 25
0.0%
0.5%
Q2 25
11.1%
0.2%
Q1 25
220.7%
0.2%
Q4 24
39.2%
1.4%
Q3 24
6.8%
0.4%
Q2 24
0.1%
0.4%
Q1 24
0.5%
0.5%
Cash Conversion
DTIL
DTIL
USCB
USCB
Q4 25
-0.56×
31.40×
Q3 25
2.25×
Q2 25
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
1.63×
Q2 24
-0.45×
2.95×
Q1 24
-2.21×
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons